Published in Liver Transpl on March 01, 2011
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int (2012) 1.46
Living-donor liver transplantation and hepatitis C. HPB Surg (2013) 0.90
Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol (2012) 0.87
Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. PLoS One (2012) 0.86
Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol (2014) 0.83
Racial differences in fibrosis progression after HCV-related liver transplantation. Transplantation (2012) 0.82
Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut (2013) 0.82
The association of IL28B polymorphism and graft survival in patients with hepatitis C undergoing liver transplantation. PLoS One (2013) 0.80
Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C. Transplantation (2014) 0.78
Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology (2014) 0.78
Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review. World J Gastroenterol (2014) 0.77
HCV in liver transplantation. Semin Immunopathol (2012) 0.76
PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics (2015) 0.75
Innate immunity: a new chapter for hepatitis C. Ann Gastroenterol (2012) 0.75
Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C. PLoS One (2014) 0.75
Predictors of disease recurrence post living donor liver transplantation in end stage chronic HCV patients. Dis Markers (2014) 0.75
Liver transplantation and hepatitis C: will understanding the interleukin-28B polymorphisms improve outcomes? Liver Transpl (2011) 0.75
Association of the interleukin-18 receptor 1 and interleukin-18 receptor accessory protein polymorphisms with the risk of esophageal cancer. Biomed Rep (2015) 0.75
Management of hepatitis C virus infection in liver transplant recipients. Gastroenterol Hepatol (N Y) (2012) 0.75
A fast and cost-effective method for identifying a polymorphism of interleukin 28B related to hepatitis C. PLoS One (2013) 0.75
Interleukin-28B TT genotype is frequently found in patients with hepatitis C virus cirrhosis but does not influence hepatocarcinogenesis. Clin Exp Med (2016) 0.75
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 14.54
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol (2008) 3.81
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 3.70
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol (2004) 3.56
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 3.46
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest (2010) 2.87
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42
Senescence rates are determined by ranking on the fast-slow life-history continuum. Ecol Lett (2008) 2.30
Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs (2007) 2.26
Biliary reconstruction using a side-to-side choledochocholedochostomy with or without T-tube in deceased donor liver transplantation: a prospective randomized trial. Ann Surg (2009) 2.19
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol (2012) 2.15
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology (2013) 2.13
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology (2015) 2.11
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol (2010) 2.09
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. Am J Transplant (2005) 2.08
Different cava reconstruction techniques in liver transplantation: piggyback versus cava resection. Hepatobiliary Pancreat Dis Int (2014) 2.08
The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C. Hepatology (2011) 2.08
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol (2011) 2.06
Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg (2009) 2.06
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet (2008) 1.98
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl (2007) 1.91
Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial. Ann Surg (2007) 1.90
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
The surgical treatment of bilateral benign nodular goiter: balancing invasiveness with complications. Dtsch Arztebl Int (2014) 1.88
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut (2012) 1.86
Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology (2002) 1.85
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology (2007) 1.79
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. Transpl Int (2009) 1.77
Hepatic artery thrombosis after adult liver transplantation. Liver Transpl (2003) 1.74
Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology (2007) 1.73
Assistance of microbial glycolipid antigen processing by CD1e. Science (2005) 1.73
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology (2011) 1.70
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS (2006) 1.68
Trends and experiences in liver retransplantation over 15 years. Liver Transpl (2007) 1.66
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology (2010) 1.65
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology (2005) 1.60
Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology (2003) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Diagnosis and treatment of arterial steal syndromes in liver transplant recipients. Liver Transpl (2003) 1.58
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis (2013) 1.58
Production of pluripotent stem cells by oocyte-assisted reprogramming: joint statement with signatories. Natl Cathol Bioeth Q (2005) 1.57
Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation (2002) 1.57
Extracorporeal liver perfusion as hepatic assist in acute liver failure: a review of world experience. Xenotransplantation (2002) 1.57
Sex is a major determinant of CYP3A4 expression in human liver. Hepatology (2003) 1.57
Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int (2011) 1.57
Safety and efficacy of new integrated bipolar and ultrasonic scissors compared to conventional laparoscopic 5-mm sealing and cutting instruments. Surg Endosc (2012) 1.57
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol (2012) 1.56
Pregnancy in primary sclerosing cholangitis. Gut (2011) 1.55
Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol (2012) 1.53
Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol (2011) 1.52
Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl (2007) 1.49
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol (2005) 1.49
Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res (2003) 1.48
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
Eighteen years of liver transplantation experience in patients with advanced Budd-Chiari syndrome. Liver Transpl (2008) 1.47
The delay of rearterialization after initial portal reperfusion in living donor liver transplantation significantly determines the development of microvascular graft dysfunction. J Hepatol (2004) 1.46
Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl (2006) 1.46
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology (2005) 1.45
Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. Radiology (2010) 1.45
The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation (2004) 1.44